Cargando…

Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience

PURPOSE: This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with prefilled pens and prefilled syringes delivering methotrexate (MTX), in patients with rheumatoid arthritis (RA). PA...

Descripción completa

Detalles Bibliográficos
Autores principales: Demary, Winfried, Schwenke, Holger, Rockwitz, Karin, Kästner, Peter, Liebhaber, Anke, Schoo, Ulrich, Hübner, Georg, Pichlmeier, Uwe, Guimbal-Schmolck, Cécile, Müller-Ladner, Ulf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130714/
https://www.ncbi.nlm.nih.gov/pubmed/25125973
http://dx.doi.org/10.2147/PPA.S64111
_version_ 1782330372926734336
author Demary, Winfried
Schwenke, Holger
Rockwitz, Karin
Kästner, Peter
Liebhaber, Anke
Schoo, Ulrich
Hübner, Georg
Pichlmeier, Uwe
Guimbal-Schmolck, Cécile
Müller-Ladner, Ulf
author_facet Demary, Winfried
Schwenke, Holger
Rockwitz, Karin
Kästner, Peter
Liebhaber, Anke
Schoo, Ulrich
Hübner, Georg
Pichlmeier, Uwe
Guimbal-Schmolck, Cécile
Müller-Ladner, Ulf
author_sort Demary, Winfried
collection PubMed
description PURPOSE: This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with prefilled pens and prefilled syringes delivering methotrexate (MTX), in patients with rheumatoid arthritis (RA). PATIENTS AND METHODS: The study (ClinicalTrials.gov number NCT01793259) enrolled 120 patients requiring initiation or intensification of MTX therapy for RA. Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses of 15, 17.5, or 20 mg MTX SC once a week for 3 weeks. This was followed by receipt of the reference drug (prefilled syringe) or the test drug (prefilled pen) in a crossover design, with each patient serving as his/her own control. Questionnaires regarding patient preference, the Self-Injection Assessment Questionnaire (SIAQ), and diaries regarding local tolerability were used to document outcomes. RESULTS: Overall patient preference for the MTX prefilled pen was 75% (P<0.0001). In a six-item questionnaire, 73% to 76% of the patients preferred the prefilled pen in relation to use, acceptability, and satisfaction, and 67% of the patients confirmed that it did not take much effort to overcome SC self-injection with the pen. The SIAQ showed no clinical differences, in any domain scores, between both devices. Overall patient attitude towards self-injection at baseline was positive, as was patient experience with both devices during the study. As well, 92% of physicians and study nurses indicated that they would recommend the MTX prefilled pen to patients for future MTX treatment. The formulations were generally well tolerated. CONCLUSION: SC self-injection of MTX with a prefilled pen was generally preferred, by patients with RA, over a prefilled syringe with regard to use, acceptability, and satisfaction. This is supported by the strong appreciation of their attending study nurses and physicians, for its convenience.
format Online
Article
Text
id pubmed-4130714
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-41307142014-08-14 Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience Demary, Winfried Schwenke, Holger Rockwitz, Karin Kästner, Peter Liebhaber, Anke Schoo, Ulrich Hübner, Georg Pichlmeier, Uwe Guimbal-Schmolck, Cécile Müller-Ladner, Ulf Patient Prefer Adherence Original Research PURPOSE: This multicenter, randomized, crossover study compared preference, ease of use, acceptability, satisfaction, and safety of repeated subcutaneous (SC) self-administrations with prefilled pens and prefilled syringes delivering methotrexate (MTX), in patients with rheumatoid arthritis (RA). PATIENTS AND METHODS: The study (ClinicalTrials.gov number NCT01793259) enrolled 120 patients requiring initiation or intensification of MTX therapy for RA. Patients were randomized to receive the test drug, a prefilled pen (Metex(®) PEN/Metoject(®) PEN), or the reference drug, a prefilled syringe (Metex(®)/Metoject(®)), at doses of 15, 17.5, or 20 mg MTX SC once a week for 3 weeks. This was followed by receipt of the reference drug (prefilled syringe) or the test drug (prefilled pen) in a crossover design, with each patient serving as his/her own control. Questionnaires regarding patient preference, the Self-Injection Assessment Questionnaire (SIAQ), and diaries regarding local tolerability were used to document outcomes. RESULTS: Overall patient preference for the MTX prefilled pen was 75% (P<0.0001). In a six-item questionnaire, 73% to 76% of the patients preferred the prefilled pen in relation to use, acceptability, and satisfaction, and 67% of the patients confirmed that it did not take much effort to overcome SC self-injection with the pen. The SIAQ showed no clinical differences, in any domain scores, between both devices. Overall patient attitude towards self-injection at baseline was positive, as was patient experience with both devices during the study. As well, 92% of physicians and study nurses indicated that they would recommend the MTX prefilled pen to patients for future MTX treatment. The formulations were generally well tolerated. CONCLUSION: SC self-injection of MTX with a prefilled pen was generally preferred, by patients with RA, over a prefilled syringe with regard to use, acceptability, and satisfaction. This is supported by the strong appreciation of their attending study nurses and physicians, for its convenience. Dove Medical Press 2014-08-06 /pmc/articles/PMC4130714/ /pubmed/25125973 http://dx.doi.org/10.2147/PPA.S64111 Text en © 2014 Demary et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Demary, Winfried
Schwenke, Holger
Rockwitz, Karin
Kästner, Peter
Liebhaber, Anke
Schoo, Ulrich
Hübner, Georg
Pichlmeier, Uwe
Guimbal-Schmolck, Cécile
Müller-Ladner, Ulf
Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
title Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
title_full Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
title_fullStr Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
title_full_unstemmed Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
title_short Subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
title_sort subcutaneously administered methotrexate for rheumatoid arthritis, by prefilled syringes versus prefilled pens: patient preference and comparison of the self-injection experience
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4130714/
https://www.ncbi.nlm.nih.gov/pubmed/25125973
http://dx.doi.org/10.2147/PPA.S64111
work_keys_str_mv AT demarywinfried subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT schwenkeholger subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT rockwitzkarin subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT kastnerpeter subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT liebhaberanke subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT schooulrich subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT hubnergeorg subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT pichlmeieruwe subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT guimbalschmolckcecile subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience
AT mullerladnerulf subcutaneouslyadministeredmethotrexateforrheumatoidarthritisbyprefilledsyringesversusprefilledpenspatientpreferenceandcomparisonoftheselfinjectionexperience